Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Intentional product misuse? 40 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 40 reports of Intentional product misuse have been filed in association with MEPOLIZUMAB (Nucala). This represents 0.1% of all adverse event reports for MEPOLIZUMAB.

40
Reports of Intentional product misuse with MEPOLIZUMAB
0.1%
of all MEPOLIZUMAB reports
23
Deaths
27
Hospitalizations

How Dangerous Is Intentional product misuse From MEPOLIZUMAB?

Of the 40 reports, 23 (57.5%) resulted in death, 27 (67.5%) required hospitalization, and 22 (55.0%) were considered life-threatening.

Is Intentional product misuse Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 40 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Product dose omission issue (5,873) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656)

What Other Drugs Cause Intentional product misuse?

ETANERCEPT (3,992) PREGABALIN (3,731) BUDESONIDE\FORMOTEROL (3,399) ACETAMINOPHEN (2,924) ESOMEPRAZOLE (2,852) MINOXIDIL (2,418) TOFACITINIB (2,331) CINACALCET (2,092) QUETIAPINE (1,855) ALPRAZOLAM (1,709)

Which MEPOLIZUMAB Alternatives Have Lower Intentional product misuse Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Intentional product misuse Reports All Drugs Causing Intentional product misuse MEPOLIZUMAB Demographics